Issues

ABOUT THE COVER
The growing cost of healthcare in oncology has incentivized researchers and physicians to repurpose clinically used drugs to reduce cost and time of development. The FDA-approved antiviral drug ribavirin epitomizes these efforts. Ribavirin has shown anticancer efficacy in preclinical and early clinical studies through various mechanisms of action including inhibition of protein translation (eIF4E), signaling pathways (ERK, MNK1), epigenetic modulators (EZH2), and cancer cell metabolism (IMPDH). Furthermore, several studies have suggested a beneficial use of ribavirin in combination with standard chemotherapies. These exciting properties position ribavirin to potentially "go viral" as a new adjuvant anticancer therapy. Image copyright owned by Johns Hopkins University, Ian Suk.